Veterinary diagnostics premium instrument placements measures the number of premium analyzers placed with veterinary customers during a period.
IDEXX reported more than 22,000 premium instrument placements in 2025, including more than 6,000 inVue Dx cellular analyzers.
Placements expand the future recurring-revenue base
Instrument revenue itself is largely non-recurring, but each placement can support future VetLab consumables revenue, service, and accessory revenue.
That makes placements a leading operating indicator for the premium instrument installed base.
Product launches can distort year-over-year placement comparisons
IDEXX said Q2 2026 instrument revenue declined partly because inVue Dx had broad commercial availability in the prior-year quarter.
A placement spike around a launch should therefore not be extrapolated mechanically into a steady-state growth rate.
Primary sources: IDEXX 2026 proxy statement and IDEXX Q2 2026 Form 10-Q.
Part of the Veterinary Diagnostics Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- IDXXOpen operating-model research →10 of 10 reviewed concepts in Veterinary Diagnostics EconomicsInstalled base, placements, and customer durability4 of 4 bridge concepts supportedContinue through this bridge:Cloud Practice Management Installed BaseCustomer Retention RatePremium Instrument Installed Base
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare diagnostic instrument placements
Compare premium instrument placements while accounting for product launches, replacement cycles, and one-time capital revenue.
Explore more topics in the Financial Research Encyclopedia.